l General Information |
Product Name | LFM-A13 |
General description | LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor (IC50 = 2.5 μM). |
Synonym | (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide |
Purity | ≥99.0%(HPLC) | CAS Number | 244240-24-2 |
Formula | C11H8Br2N2O2 | Molecular Weight | 360 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK. |
l Packaging & Storage |
Packaging | 5mg; 10mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
